Dihydrocodein

Product Description

1. Classification and Chemical Overview

Dihydrocodein (dihydrocodeine) is a semi-synthetic opioid analgesic and antitussive agent first synthesized in Germany in 1908 and commercialized internationally under proprietary names such as DF 118, DHC Continus, Dicodin, and Paracodin. Chemically designated as $(4R,4aR,7S,7aR,12bS)\text{-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,12b-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol}$, it is produced by the catalytic hydrogenation of the carbon-7 to carbon-8 double bond of codeine. This conformational reduction creates an alicyclic ring saturation that alters the orientation of the morphinan nucleus, increasing its intrinsic affinity for human opioid receptors. Its empirical formula as a free base is $\text{C}_{18}\text{H}_{23}\text{NO}_3$, with a molecular weight of $301.38\text{ g/mol}$. In pharmaceutical manufacturing, it is most commonly presented as the hydrogen tartrate salt ($\text{C}_{18}\text{H}_{23}\text{NO}_3\cdot\text{C}_4\text{H}_6\text{O}_6$, molecular weight $451.47\text{ g/mol}$) or hydrochloride salt.

Standard pharmaceutical preparations include:

• Immediate-Release Solid Formulations: Compressed tablets containing $30\text{ mg}$ or $40\text{ mg}$ of dihydrocodeine tartrate.

• Prolonged-Release Solid Formulations: Hydrophilic matrix-release tablets containing $60\text{ mg}$, $90\text{ mg}$, or $120\text{ mg}$ of dihydrocodeine tartrate designed for 12-hour sustained release.

• Oral Solutions / Elixirs: Liquid presentations delivering $10\text{ mg}$ of dihydrocodeine tartrate per $5\text{ mL}$, as well as concentrated drops ($e.g.,\text{ Paracodin drops}$ in mainland Europe).

• Combination Products: Compounded with non-opioid analgesics, such as paracetamol (e.g., Co-dydramol: $10\text{ mg}$ dihydrocodeine / $500\text{ mg}$ paracetamol or higher ratios).

Regulatory Classification

• United Kingdom: Single-entity formulations and higher-strength products are categorized as Prescription Only Medicines (POM) under the Human Medicines Regulations 2012. Under the Misuse of Drugs Act 1971, dihydrocodeine is scheduled as a Class B controlled substance. Under the Misuse of Drugs Regulations 2001, single-ingredient oral preparations and high-dose variants are placed in Schedule 2 (CD POM) (requiring full Controlled Drug prescription compliance and safe custody), while specific low-strength multi-ingredient formulations fall into Schedule 5.

• European Union (e.g., Germany, Austria, France): Regulated as a prescription-only narcotic/analgesic (Betäubungsmittel in Germany under specific ceiling thresholds; substance vénéneuse in France).

Due to its active profile on opioid-sensitive pathways, diverted dihydrocodeine is heavily targeted on illicit secondary markets. Counterfeit tablets sold as “DF 118” or “DHC” acquired via non-regulated web platforms carry acute toxicological risks of substitution with high-potency novel synthetic opioids (nitazenes) or illicit designer benzodiazepines.

2. Mechanism of Action and Pharmacodynamics

The pharmacodynamic profile of dihydrocodeine is characterized by central and peripheral $\mu$-opioid receptor (MOP) agonism, combining intrinsic activity from the parent drug with supplemental action from active Phase I and Phase II metabolites:

• $\mu$-Opioid (MOP) Receptor Agonism: Dihydrocodeine binds directly to human $\mu$-opioid receptors distributed across the dorsal horn of the spinal cord, periaqueductal gray, thalamic nuclei, and limbic structures:

  • Binding couples to pertussis toxin-sensitive inhibitory $G_{\alpha i/o}$ proteins.

  • This inhibits adenylyl cyclase, decreasing intracellular cyclic adenosine monophosphate (cAMP) production.

  • Presynaptically, it attenuates voltage-gated N-type calcium ($Ca^{2+}$) channel conductance, halting the release of nociceptive neurotransmitters (substance P, glutamate, and CGRP).

  • Postsynaptically, it stimulates G-protein-coupled inwardly rectifying potassium (GIRK) channels, inducing potassium efflux that hyperpolarizes neuronal membranes and prevents the ascending transmission of pain signals.

• Direct Intrinsic Action vs. Prodrug Profile (Contrast with Codeine):

  • While codeine has weak intrinsic $\mu$-opioid receptor affinity and acts almost entirely as a prodrug requiring bioactivation to morphine, dihydrocodeine possesses significant direct intrinsic activity.

  • Intact dihydrocodeine has approximately 10-fold higher affinity for $\mu$-opioid receptors than intact codeine.

  • Although hepatic $O$-demethylation by CYP2D6 converts a portion of the drug into dihydromorphine (which has an affinity for $\mu$-receptors roughly 70 to 100 times greater than parent dihydrocodeine), clinical studies demonstrate that the analgesic efficacy of dihydrocodeine is largely retained even in CYP2D6 poor metabolizers.

• Antitussive and Medullary Depressant Effects: Direct depressant activity at the cough center within the nucleus tractus solitarii of the medulla oblongata suppresses the cough reflex. Concurrently, $\mu$-receptor agonism within the pontomedullary respiratory pacemakers (pre-Bötzinger complex) blunts the ventilatory response to arterial carbon dioxide ($\text{CO}_2$) tension and hypoxia, driving concentration-dependent central respiratory depression.

• Relative Potency: Dihydrocodeine is considered a Step 2 opioid on the WHO analgesic ladder. It is roughly twice as potent as oral codeine ($30\text{ mg}$ oral dihydrocodeine tartrate is clinically equivalent to $\sim 60\text{ mg}$ oral codeine phosphate, or approximately $3\text{ to }5\text{ mg}$ oral morphine).

3. Approved Clinical Indications and Therapeutic Scope

Dihydrocodeine holds licensed therapeutic indications within the British National Formulary (BNF) and European pharmacopeias:

• Moderate-to-Severe Pain: Indicated for the management of acute and chronic moderate-to-severe pain where non-opioid analgesics (paracetamol, NSAIDs) have proved inadequate:

  • Immediate-Release Dosing: $30\text{ mg}$ orally every 4 to 6 hours as clinically required, taken with or after food (standard licensed maximum ceiling: $180\text{ to }240\text{ mg/day}$).

  • Prolonged-Release Dosing (e.g., DHC Continus): $60\text{ mg}$ to $120\text{ mg}$ taken every 12 hours (maximum $240\text{ mg/day}$).

• Severe, Intractable Non-Productive Cough: Indicated in specific liquid or drop formulations for suppressing non-productive, exhaustive coughing associated with bronchial carcinoma or severe respiratory conditions when non-opioid cough suppressants have failed.

• Dyspnea in Palliative Care: Prescribed off-label in specialized palliative settings to reduce the perception of breathlessness in advanced chronic obstructive pulmonary disease (COPD) or terminal malignancies.

• Opioid Substitution Therapy (Specialist Addiction Setting): Utilized off-label or under designated substitution frameworks (notably in Germany and parts of the UK) as a maintenance or tapering agent for individuals with opioid use disorder who cannot tolerate methadone or buprenorphine.

Prescribing Governance (NICE / BNF)

• Under NICE Guideline NG193 (Chronic pain in adults), the routine initiation of opioids is not recommended for chronic primary pain (e.g., fibromyalgia, non-specific lower back pain) due to lack of long-term efficacy, high dependence liabilities, and the risk of opioid-induced hyperalgesia (OIH).

• The MHRA mandates that long-term opioid prescribing for non-malignant chronic pain be periodically re-evaluated with clear tapering and exit plans.

In non-prescribed and recreational settings, dihydrocodeine is misused for its euphoric relaxation, anxiolytic detachment, and somatic sedation, or to blunt withdrawal symptoms during abstinence from more potent opioids.

4. Pharmacokinetic Profile and Metabolic Fate

The pharmacokinetic parameters of dihydrocodeine are shaped by rapid oral absorption, extensive Phase I and Phase II hepatic biotransformation, and renal clearance:

Metabolic Pathways and Pharmacogenetics

1. Glucuronidation (Major Route, $\sim 60\%$): Dihydrocodeine is directly conjugated by UDP-glucuronosyltransferase 2B7 (UGT2B7) into dihydrocodeine-6-glucuronide (DH6G), an active polar metabolite that contributes to overall analgesia.

2. $O$-Demethylation via CYP2D6 ($\sim 5\text{ to }10\%$): Converts dihydrocodeine into dihydromorphine (DHM). DHM is subsequently conjugated into dihydromorphine-3-glucuronide (DHM-3G) and dihydromorphine-6-glucuronide (DHM-6G).

3. $N$-Demethylation via CYP3A4 ($\sim 5\text{ to }10\%$): Converts dihydrocodeine to nordihydrocodeine, which has minimal therapeutic activity.

4. CYP2D6 Polymorphism Resilience: Unlike codeine—which is therapeutically ineffective in poor metabolizers (PMs) and poses life-threatening toxicity risks in ultra-rapid metabolizers (UMs)—dihydrocodeine’s direct receptor affinity ensures that its primary analgesic response remains clinically consistent across different CYP2D6 phenotypes. However, ultra-rapid metabolizers may still experience higher circulating levels of dihydromorphine, increasing the likelihood of central adverse reactions.

5. Physiological Effects and Adverse Event Spectrum

Therapeutic administration elevates the pain threshold and blunts the affective processing of nociception. However, widespread $\mu$-opioid receptor engagement produces side effects across multiple organ systems:

• Gastrointestinal and Autonomic Disturbances (Very Common, $\ge 1/10$):

  • Severe Constipation: Activation of enteric $\mu$-receptors in the myenteric plexus inhibits peristalsis, increases sphincter tone, and blunts fluid secretion. Tolerance to constipation does not develop; co-prescribing prophylactic laxatives is standard clinical protocol.

  • Nausea and vomiting: Driven by direct chemical stimulation of the chemoreceptor trigger zone (CTZ) in the area postrema.

  • Xerostomia (dry mouth) and gastrointestinal spasms.

  • Biliary spasm: Elevation of intrabiliary pressure via constriction of the Sphincter of Oddi, which can exacerbate biliary colic.

• Central Nervous System and Neuropsychiatric Effects (Common, $1/100$ to $<1/10$):

  • Somnolence, daytime drowsiness, dizziness, and cognitive clouding.

  • Euphoria or paradoxical dysphoria/restlessness.

  • Confusion, hallucinations, and sleep disturbances (more prevalent in elderly cohorts).

• Histaminergic Reactions:

  • Non-immunological mast cell degranulation causing pruritus, facial flushing, urticaria, and diaphoresis.

• Severe, Emergent and Life-Threatening Hazards (Overdose & Chronic Therapy):

  • Severe Central Respiratory Depression: Blunting of the brainstem medullary respiratory centers. Characterized by shallow bradypnea ($<8\text{ breaths/min}$), progressive cyanosis, stupor advancing to coma, hypercapnia, and fatal hypoxia.

  • Synergistic Depressant Poisoning: Fatal respiratory arrest is significantly amplified when dihydrocodeine is co-ingested with alcohol, benzodiazepines, or gabapentinoids (pregabalin, gabapentin).

  • Physical Dependence and Acute Opioid Withdrawal: Continuous use beyond 2 to 4 weeks induces down-regulation of endogenous opioid mechanisms. Abrupt cessation triggers a classical withdrawal syndrome: rhinorrhea, lacrimation, piloerection (“cold turkey”), yawning, pupillary dilation, abdominal cramps, diarrhea, tachycardia, and intense anxiety.

  • Opioid-Induced Hyperalgesia (OIH): Long-term administration can lead to paradoxically increased pain sensitivity or diffuse allodynia, requiring supervised dose reduction rather than escalation.

  • Illicit Adulteration Risks: Illicitly diverted tablets or imported syrups are increasingly adulterated with synthetic nitazene opioids, which have potencies tens to hundreds of times higher than morphine, causing rapid, severe respiratory arrest that requires higher-than-standard doses of naloxone.

6. Contraindications, Drug Interactions, and Clinical Precautions

Prescribing and toxicological evaluation of dihydrocodeine require strict adherence to opioid safety guidelines, organ-clearance assessments, and respiratory risk stratification:

• Contraindications:

  • Respiratory Compromise: Acute respiratory depression, severe chronic obstructive pulmonary disease (COPD), acute severe asthma, or compromised ventilatory drive.

  • Bowel Obstruction: Paralytic ileus, toxic megacolon, or acute obstructive bowel conditions.

  • Raised Intracranial Pressure (ICP) & Head Injury: Opioid-induced $\text{CO}_2$ retention dilates cerebral vasculature, worsening intracranial hypertension.

  • Concurrent Monoamine Oxidase Inhibitors (MAOIs): Absolute contraindication during or within 14 days of MAOI therapy due to risk of hyperpyrexic crises or central nervous system depression.

  • Severe Hepatic or Renal Impairment: Avoid or drastically reduce doses in decompensated liver disease (risk of hepatic encephalopathy) or severe renal failure (eGFR $<30\text{ mL/min/1.73 m}^2$) due to neurotoxic metabolite accumulation.

  • Pregnancy and Breastfeeding: Avoided during pregnancy unless essential (risks neonatal respiratory depression and neonatal opioid withdrawal syndrome [NOWS]); contraindicated in breastfeeding due to the passage of dihydromorphine into maternal milk.

  • Pediatric Age: Strictly contraindicated in children under 12 years of age for pain relief (and under 18 years post-tonsillectomy/adenoidectomy for obstructive sleep apnea).

• Drug Interactions:

  • Central Nervous System Depressants (Alcohol, Benzodiazepines, Z-drugs, Antipsychotics): Synergistic medullary respiratory depression, profound sedation, coma, and death.

  • Gabapentinoids (Pregabalin, Gabapentin): Markedly elevates the risk of fatal respiratory failure; requires low starting doses and close clinical monitoring.

  • CYP2D6 and CYP3A4 Inhibitors: Strong inhibitors (e.g., fluoxetine, paroxetine for CYP2D6; ketoconazole, clarithromycin for CYP3A4) alter clearance routes and active metabolite proportions, prolonging systemic half-life.

  • Anticholinergics (TCAs, Antihistamines, Antimuscarinics): Compounded risk of severe obstipation, paralytic ileus, and acute urinary retention.

• Clinical Precautions and Emergency Overdose Management (“Red Flags”):

  • Acute Overdose Resuscitation: In presentations featuring the opioid triad (respiratory depression $<8\text{ breaths/min}$, pinpoint pupils [miosis], and coma/stupor):

    • Airway and Oxygenation: Clear the airway, administer supplemental oxygen, and provide bag-valve-mask or mechanical ventilation immediately.

    • Targeted Naloxone Administration: Administer intravenous naloxone ($400\text{ mcg}$ IV initially, titrating up to $800\text{ mcg}$ to $2\text{ mg}$ every 2 to 3 minutes, up to $10\text{ mg}$ as needed) to restore spontaneous ventilation without precipitating acute withdrawal.

    • Extended Monitoring Window: Because parent dihydrocodeine and active glucuronides have elimination half-lives of $3.5\text{ to }5\text{ hours}$ (and prolonged-release DHC Continus tablets release active drug over 12 hours), patients must be monitored under continuous pulse oximetry for a minimum of 4 to 6 hours for immediate-release forms, and 12 to 24 hours for modified-release ingestions, to watch for re-narcotization as the effects of naloxone (half-life $\sim 30\text{ to }60\text{ minutes}$) wear off.

  • Laxative Co-Prescribing: Prescribers must proactively initiate a stimulating and softening laxative regimen (e.g., senna with docusate) alongside any regular dihydrocodeine therapy to prevent severe fecal impaction.

  • Discontinuation Protocols: Chronic treatment should be tapered down gradually ($e.g.,\text{ 10 to 25\% reduction every 1 to 2 weeks}$) to prevent autonomic, gastrointestinal, and psychiatric withdrawal distress.

  • Driving Safety: Patients must be advised that dihydrocodeine can impair psychomotor skills and reaction times. Under Section 5A of the UK Road Traffic Act 1988, driving with specified controlled drugs above statutory blood thresholds is an offense, though a statutory medical defense applies when the medicine is taken strictly in accordance with prescription guidelines.